Latest News From BioPharmaChem
06 March, 2012
GSK has submitted US and EU regulatory applications seeking approval of a quadrivalent influenza vaccine for the "active immunisation of adults and children from 3 years of age for the prevention of influenza disease caused by influenza virus types A and B contained in the vaccine."
13 March, 2012
Pfizer Inc. (NYSE:PFE) announced that data from a Phase 3 study of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years. These data, which are being presented today during the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in Iguacu Falls, Brazil, will support planned regulatory submissions seeking to expand the Prevnar 13 label in the United States, the European Union, and other countries around the world.
20 March, 2012
Fresh insights into how our cells multiply could help scientists develop drugs to treat cancer. Researchers have gained better understanding of the workings of two key proteins that control cell division. This process must be carried out accurately to keep cells healthy, and when it goes out of control, it can lead to cancer.
22 March, 2012
Monday March 26 to Sunday April 1, 2012
29 March, 2012
In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The study is published in Nature on Thursday 29 March 2012.